Targeting an early and substantial increase in mean arterial pressure is critical in the management of type 1 hepatorenal syndrome: A combined retrospective and pilot study

Digestive Diseases and Sciences

Volumn 59, Issue 2, 2014, Pages 471-481

  Maddukuri, Geetha ^a   Cai, Cindy X ^a,b   Munigala, Satish ^a   Mohammadi, Farnaz ^a   Zhang, Zhiwei ^a,b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Early goal directed therapy; Hepatorenal syndrome; Mean arterial pressure; Vasoconstrictor

Indexed keywords

ALBUMIN; CREATININE; MIDODRINE; NORADRENALIN; OCTREOTIDE; SERUM ALBUMIN; VASOPRESSIN;

ADULT; ARTICLE; CHILD PUGH SCORE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; FEMALE; HEPATORENAL SYNDROME; HEPATORENAL SYNDROME TYPE 1; HUMAN; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MIDDLE AGED; OVERALL SURVIVAL; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SHORT TERM SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ALBUMINS; ARTERIAL PRESSURE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; EARLY MEDICAL INTERVENTION; FEMALE; HEPATORENAL SYNDROME; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MIDODRINE; OCTREOTIDE; PILOT PROJECTS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS; VASODILATION;

EID: 84896728984     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-013-2899-z     Document Type: Article

References (21)

1. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993;105:229-236.
2. Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet. 2003;362:1819-1827.
3. Chok KS, Fung JY, Chan SC, et al. Outcomes of living donor liver transplantation for patients with preoperative type 1 hepatorenal syndrome and acute hepatic decompensation. Liver Transpl. 2012;18:779-785.
4. Restuccia T, Ortega R, Guevara M, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol. 2004;40:140-146.
5. Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology. 2005;42:439-447.
6. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999;29:1690-1697.
7. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and tips in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2004;40:55-64.
8. Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008;134:1360-1368.
9. Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology. 2002;36:941-948.
10. Martin-Llahi M, Pepin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008;134:1352-1359.
11. Duvoux C, Zanditenas D, Hezode C, et al. Effects of noradrenalin and albumin in patients with type i hepatorenal syndrome: a pilot study. Hepatology. 2002;36:374-380.
12. Giostra E, Ruedin P, Cunningham M, et al. Sustained effects of ornipressin in hepatorenal syndrome. J Hepatol. 1995;22:120-121.
13. Alessandria C, Ottobrelli A, Debernardi-Venon W, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol. 2007;47:499-505.
14. Singh V, Ghosh S, Singh B, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol. 2012;56:1293-1298.
15. Kiser TH, Fish DN, Obritsch MD, Jung R, MacLaren R, Parikh CR. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transpl. 2005;20:1813-1820.
16. Nazar A, Pereira GH, Guevara M, et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2010;51:219-226.
17. Velez JC, Nietert PJ. Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials. Am J Kidney Dis. 2011;58:928-938.
18. Boyer TD, Sanyal AJ, Garcia-Tsao G, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (hrs) type 1: relationship of serum creatinine to hemodynamics. J Hepatol. 2011;55:315-321.
19. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56:1310-1318.
20. Umgelter A, Reindl W, Franzen M, Lenhardt C, Huber W, Schmid RM. Renal resistive index and renal function before and after paracentesis in patients with hepatorenal syndrome and tense ascites. Intensive Care Med. 2009;35:152-156.
21. Malbrain ML, Cheatham ML, Kirkpatrick A, et al. Results from the international conference of experts on intra-abdominal hypertension and abdominal compartment syndrome. I. Definitions. Intensive Care Med. 2006;32:1722-1732.